Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in …
NL Albert, M Weller, B Suchorska, N Galldiks… - Neuro …, 2016 - academic.oup.com
This guideline provides recommendations for the use of PET imaging in gliomas. The review
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …
Advances in neuro-oncology imaging
KJ Langen, N Galldiks, E Hattingen… - Nature Reviews …, 2017 - nature.com
Despite the fact that MRI has evolved to become the standard method for diagnosis and
monitoring of patients with brain tumours, conventional MRI sequences have two key …
monitoring of patients with brain tumours, conventional MRI sequences have two key …
[HTML][HTML] Lomustine and bevacizumab in progressive glioblastoma
W Wick, T Gorlia, M Bendszus… - … England Journal of …, 2017 - Mass Medical Soc
Background Bevacizumab is approved for the treatment of patients with progressive
glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the …
glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the …
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version …
These joint practice guidelines, or procedure standards, were developed collaboratively by
the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and …
the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and …
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
Introduction Immunotherapy has improved outcomes for patients with non-small cell lung
cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of …
cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of …
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Summary Response Assessment in Neuro-Oncology (RANO) response criteria have been
established and were updated in 2023 for MRI-based response evaluation of diffuse …
established and were updated in 2023 for MRI-based response evaluation of diffuse …
PET imaging in neuro-oncology: An update and overview of a rapidly growing area
Simple Summary Positron emission tomography (PET) is a functional imaging technique
which plays an increasingly important role in the management of brain tumors. Owing …
which plays an increasingly important role in the management of brain tumors. Owing …
Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis
SB Strauss, A Meng, EJ Ebani… - Neuroimaging …, 2021 - neuroimaging.theclinics.com
Eighty percent of all malignant primary brain tumors diagnosed in the United States are
gliomas. 1 The current treatment paradigm for high-grade gliomas (grades III and IV) …
gliomas. 1 The current treatment paradigm for high-grade gliomas (grades III and IV) …
Current status of PET imaging in neuro-oncology
Over the past decades, a variety of PET tracers have been used for the evaluation of patients
with brain tumors. For clinical routine, the most important clinical indications for PET imaging …
with brain tumors. For clinical routine, the most important clinical indications for PET imaging …
From the clinician's point of view-What is the status quo of positron emission tomography in patients with brain tumors?
The most common type of primary brain tumor is malignant glioma. Despite intensive
therapeutic efforts, the majority of these neoplasms remain incurable. Imaging techniques …
therapeutic efforts, the majority of these neoplasms remain incurable. Imaging techniques …